Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

GenePOC Obtains FDA Clearance for its GenePOCtm Strep A Test in the US


QUÉBEC CITY, March 21, 2019 /PRNewswire/ -- GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogenetm device.

About Group A Streptococcus (GAS) infection 
GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults1. In the United States, approximately 11 to 13 thousand cases of invasive GAS disease occur each year2.

About the GenePOC Strep A assay
The GenePOC Strep A assay is a qualitative in vitro diagnostic test for the detection of Streptococcus pyogenes nucleic acids from throat swab specimens obtained from patients with signs and symptoms of pharyngitis. The assay can provide results as early as 42 minutes for positive specimens and in approximately 70 minutes for negative specimens, without the need for culture confirmation.

"The GenePOC Strep A assay demonstrated good performance during our evaluation and is a promising alternative to throat cultures and Rapid Antigen Diagnostic Tests (RADT)."
- Amanda Harrington, Medical Director of Microbiology at the Loyola University in Chicago.

It is important to note that about 11 million patients in the US are diagnosed with pharyngitis in the emergency room3. More importantly, over 70% of pharyngitis have a viral cause4. A test completed within an hour can allow physicians to better manage patients.

"The GenePOC Strep A assay can provide 'actionable' results without the need to confirm by culture. GenePOC is committed to developing important assays to complete its current offering, becoming a strong player in the field of rapid molecular diagnostics."
- Patrice Allibert, CEO of GenePOC

About revogene
revogene is an automated and stand-alone device, enabling testing of single-use proprietary microfluidic cartridges with fluorescence-based real-time polymerase chain reaction technology to deliver an accurate diagnosis.

About GenePOC
GenePOC, a member of the Debiopharm group, specializes in the development of diagnostic devices which enable the prevention and detection of infectious diseases.
Further information: www.genepoc-diagnostics.com 

About Debiopharm Group
Debiopharm Group is a global biopharmaceutical group including five companies active in life sciences. Further information: www.debiopharm.com 

Contact at GenePOC
Patrice Allibert,
CEO
211348@email4pr.com 
Tel: +1-418-650-3535

1 Bisno AL et al. Clin Infect Dis. 2002 Jul 15;35(2):113-125
2 Centers for Disease Control and Prevention (CDC) www.cdc.gov/groupastrep/surveillance.html 
3 Middleton K and Hing E. Adv Data. 2005 Dec 14;(366):1-36
4 Bower JR. Netter's Infectious Diseases 2012

SOURCE GenePOC Inc.


These press releases may also interest you

at 02:00
The University of Liverpool, Liverpool School of Tropical Medicine, and Southampton Clinical Trials Unit announced this week that they have launched their innovative COVID-19 drug testing platform, AGILE. The AGILE initiative is a collaboration...

at 01:25
Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has announced the publication of its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature...

at 01:25
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs...

at 00:30
Mydecine Innovations Group Inc. ("Mydecine" or the "Company"), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor. Dr. Reddy is one of the...

6 jui 2020
Since the beginning of the pandemic, Bainbridge Health has been closely monitoring network data to identify trends in the utilization of neuromuscular blockers, vasoactive agents, and sedatives. Through the analysis of smart infusion pump data and...

6 jui 2020
Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by...



News published on 21 march 2019 at 08:33 and distributed by: